Why the study?
What are the effective laboratory monitoring options and reversal agents for hemorrhagic patients on newer oral anticoagulants?
Population
Hemorrhagic patients on newer oral anticoagulants (dabigatran, rivaroxaban, apixaban)
Design
Review
Authors
Loading...
May guide lab selection and reversal in NOAC bleeding; leaves open need for prospective validation of strategies.
What are the effective laboratory monitoring options and reversal agents for hemorrhagic patients on newer oral anticoagulants?
This review summarizes the available laboratory monitoring options and reversal strategies for managing bleeding complications in patients taking newer oral anticoagulants.
Miyares et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: